Background-Angiotensin type 1 receptor (AT 1 R) blockers (ARB) have been shown to reduce the incidence of type 2 diabetes mellitus by an unknown molecular mechanism. The peroxisome proliferator-activated receptor-␥ (PPAR␥) is the central regulator of insulin and glucose metabolism improving insulin sensitivity. We investigated the regulation of PPAR␥ function by ARBs. Methods and Results-The ARBs irbesartan and telmisartan (10 mol/L) potently enhanced PPAR␥-dependent 3T3-L1 adipocyte differentiation associated with a significant increase in mRNA expression of the adipogenic marker gene adipose protein 2 (aP2), as measured by quantitative real-time polymerase chain reaction (irbesartan: 3.3Ϯ0.1-fold induction; telmisartan: 3.1Ϯ0.3-fold induction; both PϽ0.01). Telmisartan showed a more pronounced induction of aP2 expression in lower, pharmacologically relevant concentrations compared with the other ARBs. The ARB losartan enhanced aP2 expression only at high concentrations (losartan 100 mol/L: 3.6Ϯ0.3-fold induction; PϽ0.01), whereas eprosartan up to 100 mol/L had no significant effects. In transcription reporter assays, irbesartan and telmisartan (10 mol/L) markedly induced transcriptional activity of PPAR␥ by 3.4Ϯ0.9-fold and 2.6Ϯ0.6-fold (PϽ0.05), respectively, compared with 5.2Ϯ1.1-fold stimulation by the PPAR␥ ligand pioglitazone (10 mol/L). Irbesartan and telmisartan also induced PPAR␥ activity in an AT 1 R-deficient cell model (PC12W), demonstrating that these ARBs stimulate PPAR␥ activity independent of their AT 1 R blocking actions. Conclusions-The present study demonstrates that a specific subset of ARBs induces PPAR␥ activity, thereby promoting PPAR␥-dependent differentiation in adipocytes. The activation of PPAR␥ demonstrates new pleiotropic actions of certain ARBs, providing a potential mechanism for their insulin-sensitizing/antidiabetic effects.
A ngiotensin type 1 receptor (AT 1 R) blockers (ARBs) are widely used in the treatment of hypertension and hypertension-related cardiovascular end-organ damage. 1 In addition to their important function as antihypertensive drugs, metabolic actions of ARBs have been described. Recent clinical trials have demonstrated that AT 1 R antagonism substantially lowers the risk for type 2 diabetes compared with other antihypertensive therapies. 2 In addition, AT 1 R blockade improves insulin sensitivity in animal models of insulin resistance. 3 The underlying mechanism of the insulin-sensitizing/antidiabetic effect of ARBs is widely unknown.
The nuclear hormone receptor peroxisome proliferator-activated receptor-␥ (PPAR␥) plays an important role in the regulation of insulin sensitivity. 4 Activated by its ligands such as prostaglandins or synthetic insulin-sensitizing thiazo-lidinediones/glitazones, PPAR␥ functions as a transcriptional regulator of multiple genes involved in glucose and lipid metabolism, thereby ameliorating type 2 diabetes. 4 To elucidate the underlying mechanisms of the antidiabetic effect of ARBs, we investigated the effects of different ARBs on PPAR␥ function in 3T3-L1 cells, an established cell model to study PPAR␥ function.
Methods

Cell Culture
Mouse 3T3-L1 preadipocytes were cultured and differentiated as previously described by using a standard differentiation mixture (Mix: dexamethasone, 3-isobutyl-1-methylxanthine [IBMX], insulin, and 10% FBS). 5 Cells were treated with vehicle or the ARBs (eprosartan, irbesartan, losartan, telmisartan) until day 4 of differen-tiation. Oil Red-O staining was performed as previously described. 5 PC12W cells were cultured as previously described. 1
Semiquantitative RT-PCR and Quantitative Real-Time PCR
Real-time polymerase chain reaction (PCR) was performed as previously described with an ABI 7000 sequence detection system for real-time PCR. 6 Mouse 18S ribosomal RNA for real-time PCR and hypoxanthine guanine phosphoribosyl transferase or ␤-actin for semiquantitative reverse transcription (RT)-PCR were chosen as endogenous controls (housekeeping genes).
Transfection and Luciferase Assay
Transient transfection and luciferase assays were performed as previously described. 7 3T3-L1 cells (day 4) and PC12W cells were transfected with the use of Lipofectamine 2000 (Invitrogen) with 1 g (3T3-L1 cells) or 50 ng (PC12W cells) 3xAcyl-CoA oxidase PPAR response element (PPRE)-TK-luciferase reporter construct; PPAR␥2 (10 ng) and RXR␣ (10 ng) expression vectors, provided by Dennis Bruemmer and Ronald Law (University of California at Los Angeles) 7 ; pGal4-hPPAR␥DEF (hPPAR␥ ligand-binding domain [LBD] fused to Gal4 DBD) and pGal5-TK-pGL3, provided by Bart Staels (UR 545 INSERM, Institut Pasteur de Lille, Lille, France); and 10 ng pRL-CMV, a renilla luciferase control reporter vector. After 4 hours, transfection medium was replaced by 10% FBS DMEM plus the indicated ARBs, pioglitazone, or vehicle (dimethyl sulfoxide), and luciferase activity was measured after 24 hours.
Statistical Analysis
ANOVA and t test were performed for statistical analysis as appropriate. Statistical significance was designated at PϽ0.05. Values are expressed as meanϮSD.
Results
ARBs Promote 3T3-L1 Adipocyte Differentiation
The ARBs irbesartan (10 mol/L) and telmisartan (10 mol/L; data not shown) potently enhanced lipid accumulation, as indicated by an increased Oil Red-O staining ( Figure  1A) , and markedly induced the expression of the adipogenic marker gene adipose protein 2 (aP2) in 3T3-L1 cells in a concentration-dependent manner (irbesartan 10 mol/L plus Mix: 3.3Ϯ0.1-fold; telmisartan 10 mol/L plus Mix: 3.1Ϯ0.3-fold induction; both versus Mix alone, PϽ0.01) ( Figure 1A and 1B). Telmisartan showed a more pronounced induction of aP2 expression in low concentrations compared with the other ARBs (telmisartan EC 50 : 0.13 mol/L; irbesartan EC 50 : 3.5 mol/L) ( Figure 1B ). Losartan enhanced aP2 expression only at the highest concentration (100 mol/L: 3.6Ϯ0.3-fold induction; PϽ0.01), whereas eprosartan had no significant effects ( Figure 1B) . The PPAR␥ ligand pioglitazone stimulated aP2 expression by 4.5Ϯ1-fold (10 mol/L; PϽ0.01) compared with Mix alone ( Figure 1B) . 
ARBs Induce PPAR␥ Activity
Treatment of PPRE-transfected 3T3-L1 cells with irbesartan and telmisartan (10 mol/L) markedly induced transcriptional activity of PPAR␥ 3.4Ϯ0.9-fold and 2.6Ϯ0.6-fold, respectively (both PϽ0.05 versus vehicle-treated cells), compared with 5.2Ϯ1.1-fold stimulation by pioglitazone at the same concentration (PϽ0.01 versus vehicle-treated cells) (Data Supplement Figure, B) . Consistent with the effects on aP2 expression, losartan induced PPAR␥-dependent transcription only at high concentrations (100 mol/L: 2.2Ϯ0.46fold; PϽ0.05 versus vehicle-treated cells), and eprosartan had no effect (Data Supplement Figure, B ).
ARBs Activate the PPAR␥ LBD
To provide further insight into the mechanism whereby ARBs induce PPAR␥ activity, we assessed their ability to activate the chimeric Gal4-DBD-hPPAR␥-LBD fusion protein on a Gal4-dependent luciferase reporter. In this system, the activation of the reporter is mediated solely through activation of the PPAR␥ LBD. Treatment with the ARBs led to a concentrationdependent activation of the reporter (losartan EC 50 : Ͼ50 mol/L; irbesartan EC 50 : 26.97 mol/L; telmisartan EC 50 : 5.02 mol/L; pioglitazone EC 50 : 0.2 mol/L) (Figure 2A ).
Irbesartan and Telmisartan Induce PPAR␥ Activity Independent of the AT 1 R
To study the role of the AT 1 R blocking actions of ARBs during PPAR␥ activation, PPAR␥2 and its heterodimeric partner RXR␣ were overexpressed in an AT 1 R-deficient cell model (PC12W cells) ( Figure 2B, box) , and PPAR␥dependent transcription was measured with and without ARBs and pioglitazone. No regulation of PPAR␥ activity was observed in the absence of exogenous PPAR␥2/RXR␣ (Figure 2B) . After overexpression of the PPAR␥2/RXR␣ heterodimer, irbesartan and telmisartan also induced PPAR␥ activity in AT 1 R-deficient PC12W cells, clearly demonstrating that these compounds stimulate PPAR␥ activation independent of their AT 1 R blocking actions (irbesartan: 2.1Ϯ0.3fold; telmisartan: 1.9Ϯ0.4-fold; both PϽ0.05 versus vehicletreated cells; pioglitazone: 4.2Ϯ1.4-fold; PϽ0.01 versus vehicle-treated cells).
Discussion
The present study demonstrates that a subset of ARBs induces PPAR␥ activity by interaction with the PPAR␥-LBD, thereby promoting PPAR␥-dependent differentiation in 3T3-L1 adipocytes. Activation of PPAR␥ by these ARBs was also observed in the absence of AT 1 Rs, demonstrating that the activation is independent of blocking the AT 1 R. The induction of PPAR␥ activity demonstrates new pleiotropic actions of certain ARBs, providing a potential mechanism for their insulin-sensitizing/antidiabetic effects.
We identified ARBs with PPAR␥-activating properties at low (telmisartan), medium (irbesartan), and very high con-centrations (losartan) as well as a nonactivating ARB (eprosartan). Significant differences among the PPAR␥-activating ARBs are likely caused by their physicochemical properties. 8 High lipophilicity is required to obtain sufficiently high penetration rates to bind to intracellular PPAR␥. Telmisartan, the ARB with the highest lipophilicity, most potently induced PPAR␥-dependent aP2 expression and PPAR␥2 LBD activation at pharmacologically relevant concentrations. 8 These data imply that PPAR␥-activating potency correlates with the degree of lipophilicity among the ARBs (telmisartan Ͼ irbesartan Ͼ losartan), whereas the maximal response may depend on other characteristics. When PPAR␥-activating ARBs were compared with the PPAR␥ ligand pioglitazone, these compounds behaved like partial PPAR␥ agonists compared with the full agonism of glitazones. The detailed differences between PPAR␥-activating ARBs and glitazones will be elucidated by understanding the molecular mechanism of PPAR␥ activation by lipophilic ARBs (eg, direct binding ␤-Actin was used as a housekeeping gene. Cells from the same passages were transfected with PPRE-luciferase reporter construct with and without PPAR␥2/RXR␣ expression vectors, followed by stimulation with pioglitazone (10 mol/L), irbesartan (10 mol/L), or telmisartan (10 mol/L). Firefly luciferase activity was measured after 24 hours and normalized with activity of cotransfected renilla luciferase. Experiments were repeated 3 times; results are presented as meanϮSD. *PϽ0.05, #PϽ0.01 vs vehicle-treated cells.
to the LBD, coactivator recruitment), which remains to be determined in the future.
ARBs that activate PPAR␥ have also been demonstrated to stimulate the expression of major PPAR␥ target genes in in vivo animal models. The improvement of insulin sensitivity in obese Zucker rats by irbesartan was associated with a marked upregulation of the PPAR␥ target gene glucose transporter-4 (GLUT-4). 3, 5 These data indicate that PPAR␥ activation by ARBs translates in the regulation of PPAR␥ target genes in vivo.
Despite the effects in animal models, clinical data in insulin-resistant or diabetic patients are still limited. Hypertensive patients receiving losartan had a 25% lower rate of new-onset diabetes than the atenolol-treated group, implicating an antidiabetic action of losartan. 2 In our study losartan failed to induce PPAR␥ activity in pharmacologically relevant concentrations, suggesting additional antidiabetic mechanisms regulated by losartan or its active metabolites. Angiotensin II has been recently shown to inhibit intracellular insulin signaling, which was restored by AT 1 R antagonism. 9 Beneficial effects of ARBs on impaired insulin signaling may represent an additional molecular mechanism for insulin sensitization by these compounds. Telmisartan stimulated PPAR␥ at pharmacologically relevant concentrations. The concentrations needed for PPAR␥ activation are achieved in the plasma of hypertensive patients treated with telmisartan (280 ng/mLϭ0.54 mol/L), which will likely result in additional positive effects on insulin sensitivity in the dosages used for antihypertensive treatment. 8 Beneficial effects of telmisartan not only on insulin sensitivity but also on plasma glucose lowering as well as an improved overall diabetic situation remain to be seen in suitable in vivo models and in clinical studies.
Angiotensin-converting enzyme (ACE) inhibitors have also been shown to prevent the onset of diabetes mellitus; however, the ACE inhibitor captopril was unable to induce PPAR␥-mediated human adipocyte differentiation. 6 ACE inhibitors improve insulin sensitivity via the bradykinin pathway, which demonstrates an alternative antidiabetic mechanisms of these compounds. 10 In conclusion, PPAR␥ activation by a specific subset of ARBs may provide new therapeutic options in the treatment of patients with the metabolic syndrome. In addition, the pharmacological characteristics of PPAR␥-activating ARBs may serve as a starting point for the development of future substances combining dual functions (AT 1 R antagonism and PPAR␥ activation) to treat hypertension and insulin resistance/type 2 diabetes.
